Study of Triple-Combination Therapy Effects Using MRI in Children Ages 6 to 8 with Cystic Fibrosis

What this Trial Is About

Researchers are investigating the impact of triple-combination therapy on children aged 6 to 8 with cystic fibrosis CF. This study aims to use advanced MRI techniques to provide more sensitive and detailed measurements of lung, liver, and pancreas changes than traditional methods. These insights may help personalize treatment for younger CF patients who show mild symptoms and are clinically stable. The study uses hyperpolarized 129Xe MRI combined with traditional proton MRI to rapidly map structural and functional changes in the lungs and abdomen without sedation or radiation exposure. Participants will be assessed before starting triple-combination therapy and again after treatment to measure changes over one year. The study is non-randomized and follows patients through pre- and post-treatment imaging. During the study, children will undergo MRI scans to evaluate ventilation defects in the lungs and pancreas volume, along with other abdominal and lung measurements. Researchers will monitor changes at baseline and after one year of therapy. The study requires cooperation with MRI procedures and stability in health without recent infections or treatment changes. The total participation period includes baseline and follow-up visits over a year to track treatment response and organ changes.

BEGIN Novel ImagiNG Biomarkers